92
Participants
Start Date
December 18, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
September 30, 2026
Glecaprevir/pibrentasvir
Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
Placebo
Compounded, inactive pill equal in appearance to active study drug
RECRUITING
White River Junction VAMC, White River Junction
White River Junction Veterans Affairs Medical Center
FED